Antengene's Partner Karyopharm Therapeutics Announces Updated Data of Eltanexor in Patients with Hypomethylating Agent Refractory MDSPRNewsWire • 06/09/21
Karyopharm Announces XPOVIO® (selinexor) Is Now Available in Additional Strength TabletsPRNewsWire • 06/03/21
Karyopharm Receives Conditional Marketing Authorization in the United Kingdom (UK) for NEXPOVIO® (selinexor) in Combination with Dexamethasone for the Treatment of Adult Patients with Relapsed and or Refractory Multiple MyelomaPRNewsWire • 06/02/21
Karyopharm Announces XPOVIO® (selinexor) Data to be Presented at the 2021 American Society of Clinical Oncology Annual MeetingPRNewsWire • 05/19/21
Week In Review: Genscript And Its Legend Bio Subsidiary Raise $1 Billion From HillhouseSeeking Alpha • 05/16/21
Antengene Announces IND Approval in China for a Global Phase III Trial of Selinexor in Advanced or Recurrent Endometrial CancerPRNewsWire • 05/13/21
Antengene Announces Selinexor Added to Multiple Treatment Regimens in 2021 CSCO GuidelinesPRNewsWire • 05/06/21
Karyopharm Therapeutics Inc. (KPTI) CEO Richard Paulson on Q1 2021 Results - Earnings Call TranscriptSeeking Alpha • 05/03/21
Karyopharm Therapeutics (KPTI) Reports Q1 Loss, Lags Revenue EstimatesZacks Investment Research • 05/03/21
Karyopharm Reports First Quarter 2021 Financial Results and Highlights Recent Company ProgressPRNewsWire • 05/03/21
Karyopharm Announces the Appointment of Richard Paulson as President and Chief Executive OfficerPRNewsWire • 05/03/21
Karyopharm Announces European Medicines Agency's Validation of its Type II Variation Marketing Authorization Application for NEXPOVIO® (selinexor) in Combination with Velcade® (bortezomib) and Dexamethasone for the Treatment of Adult Patients with MultiplPRNewsWire • 04/26/21
Karyopharm Announces Publication of Health-Related Quality of Life Outcomes from Phase 3 SEAL Study of Selinexor in Advanced Unresectable Dedifferentiated Liposarcoma in Future OncologyPRNewsWire • 04/19/21
Karyopharm Stock Is Trading Higher After China's NMPA Signs Off Early-Stage ATG-019 Study In Cancer SettingsBenzinga • 04/06/21
Antengene Announces NMPA Approval of IND Application for ATG-019 in Patients with Advanced Solid Tumors or Non-Hodgkin's LymphomaPRNewsWire • 04/06/21
Karyopharm's Selinexor Receives Conditional Approval In Europe For Type Of Blood CancerBenzinga • 03/29/21
Karyopharm Receives Conditional Marketing Authorization from the European Commission for NEXPOVIO® (selinexor) in Combination with Dexamethasone for the Treatment of Adult Patients with Relapsed and or Refractory Multiple MyelomaPRNewsWire • 03/29/21
Expanded Partnership with Medidata Supports Karyopharm's Mission to Develop First-in-Class TherapeuticsBusiness Wire • 03/10/21
Antengene Announces NDA for ATG-010 (Selinexor) Granted Priority Review by China's NMPAPRNewsWire • 02/24/21
Karyopharm Therapeutics Inc. (KPTI) CEO Michael Kauffman on Q4 2020 Results - Earnings Call TranscriptSeeking Alpha • 02/11/21